Didanosine (Synonyms: 地达诺辛; 2',3'-Dideoxyinosine; ddI)

目录号: HY-B0249 纯度: 99.94%: FAQs
Data Sheet SDS COA 产品使用指南技术支持

Didanosine (2',3'-Dideoxyinosine; ddI) 是一种有效且具有口服活性的双脱氧核苷类似物，也是一种有效的核苷逆转录酶 (nucleoside reverse transcriptase) 抑制剂。Didanosine 对 HIV 显示出抗逆转录病毒活性。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Didanosine Chemical Structure

CAS No. : 69655-05-6

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥567	In-stock
5 mg	￥291	In-stock
10 mg	￥515	In-stock
50 mg	￥980	In-stock
100 mg	￥1372	In-stock
200 mg		询价
500 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Other Forms of Didanosine:

Didanosine-d₂ 询价
Didanosine (Standard) 询价

MCE 顾客使用本产品发表的 1 篇科研文献

•Int J Antimicrob Agents. 2019 Dec;54(6):814-819. [Abstract]

Didanosine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 HIV 亚型特异性产品:

查看所有亚型

HIV HIV-1 HIV-2

生物活性
纯度 & 产品资料
参考文献

生物活性

Didanosine (2',3'-Dideoxyinosine; ddI) is a a potent and orally active dideoxynucleoside analogue, and also is a potent nucleoside reverse transcriptase inhibitor. Didanosine shows antiretroviral activity for HIV^[1]^[2]^[3].

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
C8166	IC₅₀	1 μM Compound: DDI	Antiviral activity was evaluated by inhibition of HIV-1 replication in CD4+ lymphoblastoid cell line infected with HIV/IIIB strain Antiviral activity was evaluated by inhibition of HIV-1 replication in CD4+ lymphoblastoid cell line infected with HIV/IIIB strain	10.1016/0960-894X(95)00257-T
CCRF-CEM	CC₅₀	> 100 μg/mL Compound: didanosine	Cytotoxic concentration required to reduce CEM cell viability by 50% Cytotoxic concentration required to reduce CEM cell viability by 50%	[PMID: 8709116]
CCRF-CEM	CC₅₀	> 250 μM Compound: 1j; ddI	Cytotoxicity in human CEM/0 cells assessed as reduction in cell viability incubated for 4 to 5 days Cytotoxicity in human CEM/0 cells assessed as reduction in cell viability incubated for 4 to 5 days	[PMID: 32515595]
CCRF-CEM	EC₅₀	4.6 μM Compound: Ddi	Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days	[PMID: 18420310]
CEM-V	CC₅₀	> 10 μM Compound: DDI	Cytotoxic concentration required to reduce the viability of mock-infected CEM-V cells by 50% Cytotoxic concentration required to reduce the viability of mock-infected CEM-V cells by 50%	[PMID: 9240351]
H9	EC₅₀	0.0056 μM Compound: ddI	Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique	[PMID: 11430019]
H9	EC₅₀	0.0056 μM Compound: ddI	Antiviral activity against HIV1 RF in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique Antiviral activity against HIV1 RF in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique	[PMID: 11430019]
HeLa	CC₅₀	> 50 μM Compound: Dideoxyinosine	Cytotoxicity against mock-infected human HeLa cells by MTT assay Cytotoxicity against mock-infected human HeLa cells by MTT assay	[PMID: 25682562]
MT4	CC₅₀	> 100 μg/mL Compound: ddI	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 12444692]
MT4	CC₅₀	> 100 μg/mL Compound: ddI	Toxicity against human MT4 cells by MTT assay Toxicity against human MT4 cells by MTT assay	[PMID: 21658957]
MT4	CC₅₀	> 211 μM Compound: DDI	Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 21872971]
MT4	CC₅₀	> 211.66 μM Compound: DDI	Cytotoxicity against mock infected human MT4 cells after 4 days by MTT assay Cytotoxicity against mock infected human MT4 cells after 4 days by MTT assay	[PMID: 26994843]
MT4	CC₅₀	> 211.66 μM Compound: DDI	Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay	[PMID: 25240095]
MT4	CC₅₀	> 211.67 μM Compound: DDI	Cytotoxicity against human MT4 cells after 5 days MTT assay Cytotoxicity against human MT4 cells after 5 days MTT assay	[PMID: 25537532]
MT4	CC₅₀	> 212 μM Compound: DDI	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay	[PMID: 25707013]
MT4	CC₅₀	> 212 μM Compound: DDI	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay	[PMID: 25626145]
MT4	CC₅₀	> 212 μM Compound: ddI	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 28659246]
MT4	CC₅₀	> 212 μM Compound: DDI	Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 24275349]
MT4	CC₅₀	> 212 μM Compound: Didanosine	Cytotoxicity against human MT4 cells after 5 days MTT assay Cytotoxicity against human MT4 cells after 5 days MTT assay	[PMID: 27112451]
MT4	CC₅₀	> 425 μM Compound: ddI	Concentration required to reduce the viability of mock-infected MT-4 cells by 50% (4 days) Concentration required to reduce the viability of mock-infected MT-4 cells by 50% (4 days)	[PMID: 7523675]
MT4	CC₅₀	> 50 μg/mL Compound: DDI	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	[PMID: 27214512]
MT4	CC₅₀	> 50 μg/mL Compound: DDN, DDI	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	10.1007/s00044-013-0567-7
MT4	CC₅₀	> 50 μM Compound: dideoxyinosine	Cytotoxicity against human MT4 cells assessed as inhibition of cell metabolism after 72 hrs by MTS assay Cytotoxicity against human MT4 cells assessed as inhibition of cell metabolism after 72 hrs by MTS assay	[PMID: 25946116]
MT4	CC₅₀	> 50 μM Compound: dideoxyinosine	Cytotoxicity against human MT4 cells assessed as inhibition of overall cell metabolism after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as inhibition of overall cell metabolism after 5 days by MTT assay	[PMID: 24926807]
MT4	CC₅₀	> 500 μM Compound: ddI	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 23419738]
MT4	CC₅₀	> 529 μM Compound: DDI	Cytotoxicity against human MT4 cells after 4 days by MTT assay Cytotoxicity against human MT4 cells after 4 days by MTT assay	[PMID: 20638854]
MT4	CC₅₀	≥ 529 μM Compound: DDI	Cytotoxicity against human MT4 cells after 4 days by MTT assay Cytotoxicity against human MT4 cells after 4 days by MTT assay	[PMID: 17869386]
MT4	CC₅₀	≥ 529 μM Compound: DDI	Cytotoxicity against MT4 cells after 4 days by MTT method Cytotoxicity against MT4 cells after 4 days by MTT method	[PMID: 17095124]
MT4	CC₅₀	≥ 529 μM Compound: DDI	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 18692274]
MT4	CC₅₀	≥ 529 μM Compound: DDI	Cytotoxic concentration that reduces the MT-4 cell viability by 50% Cytotoxic concentration that reduces the MT-4 cell viability by 50%	[PMID: 15149669]
MT4	EC₅₀	0.46 μg/mL Compound: ddl	In vitro evaluation of antiviral activity against HSV-1 (Herpes simplex virus-1) induced cytopathic effect in MT-4 cells by indirect immunofluorescence assay In vitro evaluation of antiviral activity against HSV-1 (Herpes simplex virus-1) induced cytopathic effect in MT-4 cells by indirect immunofluorescence assay	10.1016/0960-894X(95)00395-A
MT4	IC₅₀	10.8 μM Compound: dideoxyinosine	Antiviral activity against Human immunodeficiency virus 1 3b infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay Antiviral activity against Human immunodeficiency virus 1 3b infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay	[PMID: 24926807]
MT4	EC₅₀	10.8 μM Compound: dideoxyinosine	Antiviral activity against HIV1-3B infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay Antiviral activity against HIV1-3B infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay	[PMID: 25946116]
MT4	CC₅₀	1053 μM Compound: DDI	Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%. Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%.	[PMID: 1995896]
MT4	EC₅₀	11 μg/mL Compound: ddI	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 12444692]
MT4	EC₅₀	15.33 μM Compound: DDI	Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24055077]
MT4	EC₅₀	16 μM Compound: DDI	Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 21872971]
MT4	EC₅₀	17.19 μM Compound: DDI	Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24055077]
MT4	IC₅₀	17.95 μg/mL Compound: Didanosine	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenic effect after 5 days by MTT assay	[PMID: 27105027]
MT4	EC₅₀	18 μM Compound: DDI	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay	[PMID: 24275349]
MT4	EC₅₀	19 μM Compound: DDI	Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay	[PMID: 24275349]
MT4	IC₅₀	2.09 μg/mL Compound: DDN, DDI	Antiviral activity against HIV1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	10.1007/s00044-013-0567-7
MT4	EC₅₀	2.09 μg/mL Compound: DDI	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay	[PMID: 27214512]
MT4	EC₅₀	2.1 μg/mL Compound: ddI	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 12444692]
MT4	EC₅₀	2.27 μM Compound: Dideoxyinosine	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	[PMID: 25682562]
MT4	IC₅₀	2.31 μg/mL Compound: ddI	Antiviral activity against HIV1 3B infected in human MT4 cells coinjected with HTLV1 assessed as reduction in virus induced cytopathicity measured 5 days post infection by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells coinjected with HTLV1 assessed as reduction in virus induced cytopathicity measured 5 days post infection by MTT assay	[PMID: 21658957]
MT4	EC₅₀	2.56 μM Compound: Dideoxyinosine	Antiviral activity against HIV1 3B infected infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B infected infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	[PMID: 25682562]
MT4	IC₅₀	2.71 μM Compound: DDI	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 20638854]
MT4	IC₅₀	2.71 μM Compound: DDI	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 18692274]
MT4	IC₅₀	2.71 μM Compound: DDI	Antiviral activity against HIV2 ROD in MT4 cells after 4 days by MTT method Antiviral activity against HIV2 ROD in MT4 cells after 4 days by MTT method	[PMID: 17095124]
MT4	IC₅₀	2.71 μM Compound: DDI	Antiviral activity against HIV2 ROD in human MT4 cells assessed as inhibition of viral replication by MTT assay Antiviral activity against HIV2 ROD in human MT4 cells assessed as inhibition of viral replication by MTT assay	[PMID: 17869386]
MT4	IC₅₀	2.71 μM Compound: DDI	Concentration required to protect the cell against HIV-2 strain ROD viral cytopathogenicity by 50% in MT-4 cells Concentration required to protect the cell against HIV-2 strain ROD viral cytopathogenicity by 50% in MT-4 cells	[PMID: 15149669]
MT4	CC₅₀	211.69 μM Compound: DDI	Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 24055077]
MT4	EC₅₀	23 μM Compound: Didanosine	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 27112451]
MT4	EC₅₀	23 μM Compound: DDI	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25707013]
MT4	EC₅₀	23.2 μM Compound: DDI	Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25537532]
MT4	EC₅₀	23.2 μM Compound: DDI	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 25240095]
MT4	EC₅₀	23198 nM Compound: DDI	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25626145]
MT4	IC₅₀	3.78 μg/mL Compound: DDN, DDI	Antiviral activity against HIV2 ROD infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV2 ROD infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	10.1007/s00044-013-0567-7
MT4	EC₅₀	3.78 μg/mL Compound: DDI	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay	[PMID: 27214512]
MT4	EC₅₀	34.7 μM Compound: ddI	Antiviral activity against Human immunodeficiency virus 2 ROD infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against Human immunodeficiency virus 2 ROD infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	[PMID: 23419738]
MT4	EC₅₀	44.91 μM Compound: DDI	Antiviral activity against wild type HIV-2 ROD infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against wild type HIV-2 ROD infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25537532]
MT4	EC₅₀	44.91 μM Compound: DDI	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 25240095]
MT4	IC₅₀	5.37 μM Compound: DDI	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 20638854]
MT4	IC₅₀	5.37 μM Compound: DDI	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 18692274]
MT4	IC₅₀	5.37 μM Compound: DDI	Antiviral activity against HIV1 3B in MT4 cells after 4 days by MTT method Antiviral activity against HIV1 3B in MT4 cells after 4 days by MTT method	[PMID: 17095124]
MT4	IC₅₀	5.37 μM Compound: DDI	Antiviral activity against HIV 3B in human MT4 cells assessed as inhibition of viral replication by MTT assay Antiviral activity against HIV 3B in human MT4 cells assessed as inhibition of viral replication by MTT assay	[PMID: 17869386]
MT4	IC₅₀	5.37 μM Compound: DDI	Concentration required to protect the cell against HIV-1 strain IIIB viral cytopathogenicity by 50% in MT-4 cells Concentration required to protect the cell against HIV-1 strain IIIB viral cytopathogenicity by 50% in MT-4 cells	[PMID: 15149669]
MT4	IC₅₀	5.76 μg/mL Compound: ddI	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as reduction in virus induced cytopathicity measured 5 days post infection by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as reduction in virus induced cytopathicity measured 5 days post infection by MTT assay	[PMID: 21658957]
MT4	CC₅₀	50 μg/mL Compound: Didanosine	Cytotoxicity against human MT4 cells infected with HIV1 3B assessed as cell growth inhibition after 5 days by MTT assay Cytotoxicity against human MT4 cells infected with HIV1 3B assessed as cell growth inhibition after 5 days by MTT assay	[PMID: 27105027]
MT4	EC₅₀	7.8 μM Compound: ddI	Antiviral activity against Human immunodeficiency virus 1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against Human immunodeficiency virus 1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	[PMID: 23419738]
MT4	EC₅₀	75.99 μM Compound: DDI	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as cell viability after 4 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as cell viability after 4 days by MTT assay	[PMID: 26994843]
MT4	EC₅₀	8.85 μM Compound: DDI	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 27234889]
MT4	EC₅₀	8.86 μM Compound: DDI	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 21872971]
MT4	EC₅₀	82.12 μM Compound: DDI	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as cell viability after 4 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as cell viability after 4 days by MTT assay	[PMID: 26994843]
MT4	IC₅₀	9.6 μM Compound: dideoxyinosine	Antiviral activity against Human immunodeficiency virus type 2 ROD infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay Antiviral activity against Human immunodeficiency virus type 2 ROD infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay	[PMID: 24926807]
MT4	EC₅₀	9.6 μM Compound: dideoxyinosine	Antiviral activity against HIV2-ROD infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay Antiviral activity against HIV2-ROD infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay	[PMID: 25946116]
PBMC	IC₅₀	< 5 μM Compound: 2a	Anti-HIV activity measured as the ability to inhibit HIV -1 p24 Gag protein production, using PHA/PBM system. Anti-HIV activity measured as the ability to inhibit HIV -1 p24 Gag protein production, using PHA/PBM system.	[PMID: 7707321]
PBMC	IC₅₀	0.003418 mM Compound: 1, DDI, Didanosine	Antiviral activity against wild type HIV-1 isolate infected in human PBMC cells assessed as inhibition of viral production by p24 antigen production/ELISA Antiviral activity against wild type HIV-1 isolate infected in human PBMC cells assessed as inhibition of viral production by p24 antigen production/ELISA	10.1039/C4MD00003J
PBMC	IC₅₀	0.04 mM Compound: 1, DDI, Didanosine	Antiviral activity against HIV-1 HTLV-3B infected in human PBMC cells assessed as inhibition of viral production by p24 antigen production/ELISA Antiviral activity against HIV-1 HTLV-3B infected in human PBMC cells assessed as inhibition of viral production by p24 antigen production/ELISA	10.1039/C4MD00003J
PBMC	IC₅₀	2.863 mM Compound: 1, DDI, Didanosine	Antiviral activity against NRTI-resistant HIV-1 D67N, T69D, K70R, A98G, V118I, M184V, T215F and K219Q mutant isolate infected in human PBMC cells assessed as inhibition of viral production by p24 antigen production/ELISA Antiviral activity against NRTI-resistant HIV-1 D67N, T69D, K70R, A98G, V118I, M184V, T215F and K219Q mutant isolate infected in human PBMC cells assessed as inhibition of viral production by p24 antigen production/ELISA	10.1039/C4MD00003J
WI-38	CC₅₀	> 100 μM Compound: Didanosine	Cytotoxicity against human WI38 cells by neutral red assay Cytotoxicity against human WI38 cells by neutral red assay	[PMID: 18285481]
WI-38	EC₅₀	> 100 μM Compound: Didanosine	Antimicrobial activity against BK polyomavirus ATCC VR837 infected in human WI38 cells assessed as reduction in viral titer after 7 days by PCR analysis Antimicrobial activity against BK polyomavirus ATCC VR837 infected in human WI38 cells assessed as reduction in viral titer after 7 days by PCR analysis	[PMID: 18285481]

体外研究
(In Vitro)

Didanosine is converted by cellular enzymes to the active antiviral metabolite dideoxyadenosine triphosphate (dd-ATP) and the intracellular half life of dd-ATP varies from 8-24 hours^[1].
Didanosine shows antiretroviral activity with IC₅₀ value of 0.24-0.6 mg/L for HIV infection^[3].
Didanosine (5, 10, 50, 100 ug/ml; 24, 48 h) shows no significant inhibition of cell proliferation in IEC-6 cells^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[2]

Cell Line:	IEC-6 cells
Concentration:	5, 10, 50, 100 ug/ml
Incubation Time:	24, 48 h
Result:	Did not show any significant inhibition of cell proliferation at either 24 h or 48 h.

Apoptosis Analysis^[2]

Cell Line:	IEC-6 cells
Concentration:	100 ug/ml
Incubation Time:	24 h
Result:	Induced apoptosis with the apoptosis rates of 4.7% to 7.4%.

体内研究
(In Vivo)

Didanosine (100, 150 mg/kg; p.o.; daily for 7 days) decreases the length of duodenal and in jejunal villus in mouse^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	30-40 g, male swiss mice^[2]
Dosage:	100, 150 mg/kg
Administration:	P.o.; daily for 7 days
Result:	Caused significant reductions in duodenal and in jejunal villus length and significantly decreased ileal crypt depth.

Clinical Trial

分子量

236.23

Formula

C₁₀H₁₂N₄O₃

CAS 号

69655-05-6

性状

固体

颜色

White to off-white

中文名称

去羟肌苷；地达诺新；地丹诺辛

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

细胞实验：

DMSO 中的溶解度 : 62.5 mg/mL (264.57 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	4.2332 mL	21.1658 mL	42.3316 mL
5 mM	0.8466 mL	4.2332 mL	8.4663 mL
10 mM	0.4233 mL	2.1166 mL	4.2332 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (8.80 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (8.80 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (8.80 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.94%

选择批次：

Data Sheet (628 KB) SDS (252 KB)

COA (288 KB) LCMS (266 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Munir N.Nassar, et al. Analytical profiles of drug substances and excipients. Journals & Books, 1993, 185-227.

[2]. Braga Neto MB, et al. Evaluation of HIV protease and nucleoside reverse transcriptase inhibitors on proliferation, necrosis, apoptosis in intestinal epithelial cells and electrolyte and water transport and epithelial barrier function in mice. BMC Gastroenterol. 2010 Aug 11;10:90. [Content Brief]

[3]. Caroline M. Perry, et al. Didanosine. Drugs, 1999, 58, 1099-1135.

Didanosine 相关分类

Infection

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	4.2332 mL	21.1658 mL	42.3316 mL	105.8291 mL
	5 mM	0.8466 mL	4.2332 mL	8.4663 mL	21.1658 mL
	10 mM	0.4233 mL	2.1166 mL	4.2332 mL	10.5829 mL
	15 mM	0.2822 mL	1.4111 mL	2.8221 mL	7.0553 mL
	20 mM	0.2117 mL	1.0583 mL	2.1166 mL	5.2915 mL
	25 mM	0.1693 mL	0.8466 mL	1.6933 mL	4.2332 mL
	30 mM	0.1411 mL	0.7055 mL	1.4111 mL	3.5276 mL
	40 mM	0.1058 mL	0.5291 mL	1.0583 mL	2.6457 mL
	50 mM	0.0847 mL	0.4233 mL	0.8466 mL	2.1166 mL
	60 mM	0.0706 mL	0.3528 mL	0.7055 mL	1.7638 mL
	80 mM	0.0529 mL	0.2646 mL	0.5291 mL	1.3229 mL
	100 mM	0.0423 mL	0.2117 mL	0.4233 mL	1.0583 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Didanosine69655-05-62',3'-Dideoxyinosine ddI去羟肌苷地达诺新地丹诺辛HIVReverse TranscriptaseHuman immunodeficiency virusantiretroviralapoptosisIEC-6 cellsorally activeInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Didanosine (Synonyms: 地达诺辛; 2',3'-Dideoxyinosine; ddI)

Other Forms of Didanosine:

MCE 顾客使用本产品发表的 1 篇科研文献

Didanosine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 HIV 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Didanosine 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Didanosine (Synonyms: 地达诺辛; 2',3'-Dideoxyinosine; ddI)

Other Forms of Didanosine:

Didanosine 相关抗体

MCE 顾客使用本产品发表的 1 篇科研文献

Didanosine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 HIV 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

Didanosine 相关抗体:

摩尔计算器

稀释计算器

Didanosine 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z